Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1123 - Retrospective Analysis of Outcome in GIST patients on Imatinib in Sarawak General Hospital: A Single Institution Experience


24 Nov 2018


Poster display - Cocktail


Cytotoxic Therapy;  Targeted Therapy

Tumour Site



Ying Ying Sum


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


Y.Y. Sum1, U. Nagaswara1, S.K. Kho1, C.J. Lim2, Y. Junie Khoo1

Author affiliations

  • 1 Radiotherapy And Oncology, Sarawak General Hospital, 93586 - Kuching/MY
  • 2 Clinical Research Centre, Sarawak General Hospital, 93586 - Kuching/MY


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1123


Gastrointestinal stromal tumours (GISTs) are the commonest mesenchymal tumours in the gastrointestinal tract. A paradigm of molecularly targeted therapy in GISTs made imatiniban effective therapy. This study aims to analyse treatment outcomes of GIST patients treated with imatinib in Sarawak General Hospital (SGH) and todetermine prognostic factors associated with survivals.


Fifty patients diagnosed with GIST for treatment with imatinib were included in this retrospective study. Patient data were retrieved from clinic records, pharmacy census and GIST patient database.


In our cohort, male predominance was observed (60%) with mean age of 57.7 years old. The commonest primary site is stomach (48%) followed by small bowel (24%).70% patients are diagnosed as advanced GIST, metastasis seen primarily in the liver (68.6%). Imatinib dose adjustment was required in 14 (28%) patients, 64.3% due to disease progression and 35.7% due to toxicity. Anaemia (36%) is the commonest reported side effect followed by skin toxicity (20%) and neutropenia (16%). The median survivalfor patients was 301.21 days using Kaplan Meier analysis whereas median progression free survival was 105 days. Log Rank test for survival of different treatment post progression showed significant difference in survival between imatinib dose escalation versus best supportive care(X2 statistics: 4.263; p = 0.039).However, no significant difference wasseen between imatinib dose escalations versus second line Sunitinib(X2 statistics: 1.471; p = 0.225). The table illustrates prognostic factors associated with survival using Simple Cox Regression.Table: 116P

VariablesHR (95% CI)P value
Age0.964 (0.903, 1.029)0.271
Gender Female Male1.00 1.183 (0.290, 4.827)0.814
ECOG4.071 (0.725, 22.879)0.111
Size 5-10CM >10CM1.00 0.408 (0.084, 1.987)0.267
Distant Metastasis No Yes1.00 2.327(0.272,19.889)0.440
Mitotic Index (MI/50hpf) <5 >101.00 2.035 (0.364, 11.390)0.419


From our study, we conclude that poor ECOG, high mitotic index and advanced GIST carry higher risk to death numerically. Imatinib dose escalation upon progression has significantly better survival compared to best supportive care.

Editorial acknowledgement

Clinical trial identification

NMRR ID 40174.

Legal entity responsible for the study

MREC/NMRR Malaysia.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.